⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 1, 2026Drug Design Development and TherapyOpen Access

The Pan-Inhibitor of Aurora Kinases Danusertib Induces Apoptosis and Autophagy and Suppresses Epithelial-to-Mesenchymal Transition in Human Breast Cancer Cells [Retraction]

Jin-Ping Li Yin-Xue Yang Qilun Liu Z Zhou Pan S Zhi-Xu He Xueji Zhang Tianxin Yang Pan S Wei Duan Shuming He Xiao‐Wu Chen Jia-Xuan Qiu Shu-Feng S Zhou

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aimed to investigate the effects of danusertib on apoptosis, autophagy, and epithelial-to-mesenchymal transition in breast cancer cells.
Used cytometry plots to analyze different proteins and experimental conditions.
Evaluated the impact of danusertib on key cellular processes in breast cancer cells.
Observed induction of apoptosis and autophagy in response to danusertib treatment.
Noted suppression of epithelial-to-mesenchymal transition in breast cancer cells.

Implication

Retraction of findings on how danusertib affects apoptosis and EMT in breast cancer cells, indicating potential implications.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a3630f5db0793dc1a537f1f https://doi.org/10.2147/dddt.s633634

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Plumbagin Induces Cell Cycle Arrest and Autophagy and Suppresses Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR-Mediated Pathway in Human Pancreatic Cancer Cells [Retraction]Original Research · 2026
2Alisertib Induces Cell Cycle Arrest and Autophagy and Suppresses Epithelial-to-Mesenchymal Transition Involving PI3K/Akt/mTOR and Sirtuin 1-Mediated signaling pathways in Human Pancreatic Cancer Cells [Retraction]Original Research · 2026
3Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
4Supplementary Figure S4 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus2024
5Supplementary Figure S4 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer2024